Oxytocin

Specifications

50-56-6CAS Number

200-048-4EC Number

(2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-IUPAC Name

C43H66N12O12S2Chemical Formula

1007.2 g/molMolecular Weight

OXYTOCIN; 50-56-6; Pitocin; Endopituitrina; Ocytocin; Syntocinon; Oxytocinum; Orasthin; Oxitocina; Oxystin; Oxytocine; alpha-Hypophamine; Synthetic oxytocin; Piton S; (1-Hemicystine)oxytocin; Syntocinone; Presoxin; Syntocin; Uteracon; Di-sipidin; Nobitocin S; 3-Isoleucine-8-leucine vasopressin; Atonin O; Intertocine S; DTXSID8048361; 1JQS135EYN; Vasopressin, 3-L-isoleucine-8-L-leucine-; CHEBI:7872; (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide; OXYTOCIN 5 USP UNITS IN DEXTROSE 5%; OXYTOCIN 10 USP UNITS IN DEXTROSE 5%; OXYTOCIN 20 USP UNITS IN DEXTROSE 5%; TNX1900; TTA-121; TNX-1900; Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2, cyclic 1-6 disulfide; L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic (1-6)-disulfide; 1-({(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-[(1S)-1-methylpropyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl}carbonyl)-L-prolyl-L-leucylglycinamide; Oxytocin Injectable; (2S)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-((2S)-butan-2-yl)-16-((4-hydroxyphenyl)methyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl)-N-((2S)-1-((2-amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)pyrrolidine-2-carboxamide; (2S)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-((2S)-butan-2-yl)-16-((4-hydroxyphenyl)methyl)-6,9,12,15,18-pentaoxo1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl)-N-((2S)-1-((2-amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)pyrrolidine-2-carboxamide; (2S)-1-[(4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]pyrrolidine-2-carboxamide; 1-(((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-16-(4-hydroxybenzyl)-13-((1S)-1-methylpropyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl)carbonyl)-L-prolyl-L-leucylglycinamide; Recombinant Oxytocin; oxytocin, for bioassay; RefChem:6091; PVL Oxytocin Injectable; Oxytocin (High Potency Powder); DTXCID4028335; H01BB02; Oxytocin (Label Under Distributors); 200-048-4; C43H66N12O12S2; MFCD00076731; CHEMBL395429; Partocon; L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic (1-->6)-disulfide; OXT; Ocytocinum; Ossitocina; Oxetakain; Oxoject; Synpitan; Utedrin; [3H]oxytocin; Oxetakain [Czech]; L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic(1-6)-disulfide; Ossitocina [DCIT]; Oxytocine [INN-French]; Oxytocinum [INN-Latin]; Oxitocina [INN-Spanish]; UNII-1JQS135EYN; Vasotocin;; [3H]OT (human, mouse, rat); HSDB 2182; Oxytocin [USP:INN:BAN:JAN]; Oxytocin CRS; Nobitocin S.; Syntocinon (TN); Atonin O;; Oxytocin (TN); EINECS 200-048-4; Pitocin (TN); CYIQNCPLG; BRN 3586108; SCHEMBL29048; Oxytocin (JP18/USP/INN); Alpha-Hypophamine; Syntocinon;; GTPL2174; GTPL2176; orb1302159; SCHEMBL27648974; BCBcMAP01_000094; WZG0206; MSK10463; BDBM50205990; HB2929; TI-001; AKOS015994657; FO35402; HS-2021; ane-4-carbonyl)pyrrolidine-2-carboxamide; NCGC00167132-01; AC-28730; BP-50422; HY-17571; SY102952; O9497; C00746; D00089; SBI-0654087.0001; Q169960; SR-01000945111; SR-01000945111-1; BRD-K25243230-001-01-2; Oxytocin, European Pharmacopoeia (EP) Reference Standard; (Gly-9 = C-terminal amide, disulfide bridge between 1 - 6); 5,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicos; Oxytocin, United States Pharmacopeia (USP) Reference Standard; Oxytocin, lyophilized powder, ~15 IU/mg solid (Prepared from synthetic oxytocin); (S)-N-((S)-1-((2-amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-((S)-sec-butyl)-16-(4-hydroxybenzyl)-6,9,12,1; (S)-N-((S)-1-((2-amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-((S)-sec-butyl)-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicos; (S)-N-((S)-1-((2-Amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)-1-((4R,7S,10S,13S,16S,19R)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-((S)-sec-butyl)-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl)pyrrolidine-2-carboxamide; 1-{(4R,7S,10S,13S,16S,19R)-19-Amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-[(2S)-butan-2-yl]-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carbonyl}-L-prolyl-L-leucylglycinamide; L-Cysteinyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucylglycinamide cyclic (1 inverted exclamation marku6)-disulfide; Otx; Oxytocin Concentrate SolutionSynonyms